Hematopoietic Stem Cells

People

Peter Kurre, MD

Photo of Peter Kurre, MD
Principal Investigator

With extended training in Pediatric Hematology, Oncology and Stem Cell Transplantation at Fred Hutchinson Cancer Research Center, Dr. Kurre’s clinical work is now focused on children with bone marrow failure. He strives to provide excellence in care for families and patients across a wide spectrum of inherited and acquired conditions that lead to loss of blood formation. As a Physician Scientist, both clinical and scientific goals of his work are therefore directed at improving understanding and broadening treatment options for patients with bone marrow failure. Dr. Kurre’s laboratory has longstanding expertise in Fanconi Anemia (FA), a genetic condition with prominent hematologic complications. With training in transplantation and hematopoietic stem cell biology, he hopes to improve our understanding of the progressive hematopoietic failure in patients with BMF and FA, and broaden diagnostic approaches, and develop next generation therapies.

Ding-Wen Chen, PhD

Ding-Wen Chen, PhD
Postdoctoral Fellow

Dr. Chen completed his PhD at the University of Waterloo in 2018 with research training at the interface of drug delivery, gene therapy, nanomedicine and regenerative medicine. As a postdoctoral fellow at Kurre’s laboratory, Dr.

Theresa Menna

Photo of Theresa Menna
Research Technician

Theresa Menna, BS, became a Research Technician for the Bone Marrow Failure Center in December 2018. Her role is to design and conduct experiments in tissue culture and mouse models to further understand the processes in hematopoietic stem cells that contribute to Fanconi Anemia.

Research

  • Understand cause of stem cell losses in Fanconi Anemia.
    • Failure of the hematopoietic system with stem cell losses is a near uniform occurrence in FA. The etiology remains unknown and we are using murine models to understand the underlying defect
  • The role of FA proteins during hematopoietic development Hematopoietic development in bone marrow failure diseases is poorly understood and fetal deficits remain to be elucidated.
    • As hematopoietic stem cells undergo maturation to an adult phenotype well after birth, therapeutic opportunities that focus on fetal characteristics may reveal additional therapeutic opportunities.
  • The role of cell-derived extracellular vesicles in stem cell regulation.
    • Cell derived vesicles are constitutively released by cells. The transmission of protein an RNA cargo to other cells in both paracrine and endocrine manner has revealed potent regulatory capacity. We are beginning to study their role in HSC regulation in several loss and gain of function models.